Clinical Trial

A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA® (Levonorgestrel and Ethinyl Estradiol) Transdermal System

Completed Phase 4
View on ClinicalTrials.gov →
Summary
The objective of this open-label study was to assess residual EE and LNG content on used Twirla® TDSs, packaging, and the skin surface at the application site after 7 full days of wear and the estimate EE and LNG loaded on control TDSs using valid analytical methods.
Trial Details
NCT Number NCT07739589
Lead Sponsor Insud Pharma
Collaborators: Agile Therapeutics, TKL Research, Inc.
Conditions Residual Drug Amount of EE and LNG
Enrollment 28 participants
Start Date 2021-10-25
Primary Completion 2021-11-16 (estimated)
Study Completion 2021-11-16 (estimated)
Updated on ClinicalTrials.gov 2026-07-31